Immunotherapy with antibody-targeted HLA class I complexes: results of in vivo tumour cell killing and therapeutic vaccination.

Immunotherapy with antibody-targeted HLA class I complexes: results of in vivo tumour cell killing and therapeutic vaccination.

BACKGROUND: The delivery of antibody-targeted major histocompatibility complex (MHC) class I complexes containing immunogenic peptides to the surface of tumour cells allows cytotoxic T lymphocytes (CTLs) of non-tumour specificity to recognise and kill the tumour cell. Previous studies have demonstra...

Full description

Bibliographic Details
Main Authors:	Savage, P, Dyson, J, Milrain, M, Mathews, D, King, B, Chan, H, Barber, L, Epenetos, A, Ogg, G, McMichael, A, Glennie, M, French, R
Format:	Journal article
Language:	English
Published:	2007

Similar Items

Induction of viral and tumour specific CTL responses using antibody targeted HLA class I peptide complexes.
by: Savage, P, et al.
Published: (2002)

Application of HLA class I single chain trimers for leukaemia immunotherapy
by: Kotsiou, E, et al.
Published: (2008)

In vivo discovery of immunotherapy targets in the tumour microenvironment
by: Zhou, Penghui, et al.
Published: (2014)

Anti-viral cytotoxic T cells inhibit the growth of cancer cells with antibody targeted HLA class I/peptide complexes in SCID mice.
by: Savage, P, et al.
Published: (2002)

Simplified one-step antibody-HLA directed expansion of HIV-specific cytotoxic T lymphocytes: a system suited for use in vivo.
by: Stebbing, J, et al.
Published: (2004)

Use of B cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen.
by: Savage, P, et al.
Published: (2004)

The arrival of HLA class II tetramers.
by: Mcmichael, A, et al.
Published: (1999)

Sensitization of tumour cells to lysis by virus-specific CTL using antibody-targeted MHC class I/peptide complexes.
by: Ogg, G, et al.
Published: (2000)

HLA-peptide tetrameric complexes.
by: Ogg, G, et al.
Published: (1998)

Targeting the hypoxic tumour phenotype with T-cell immunotherapy
by: Chong, T
Published: (2004)

INTERACTIONS BETWEEN PEPTIDE AND CLASS-I MHC - IMPLICATIONS FOR IMMUNOTHERAPY IN RHEUMATIC DISEASE
by: Moots, R, et al.
Published: (1993)

INTERACTIONS BETWEEN PEPTIDE AND CLASS-I MHC - IMPLICATIONS FOR IMMUNOTHERAPY IN RHEUMATIC DISEASE
by: Moots, R, et al.
Published: (1993)

An HLA class I specific monoclonal antibody that fails to bind to all HLA-A antigens.
by: Ellis, SA, et al.
Published: (1985)

HLA class I antigens in severe RSV bronchiolitis.
by: Isaacs, D, et al.
Published: (1989)

MHC-II neoantigens shape tumour immunity and response to immunotherapy
by: Luoma, Adrienne M., et al.
Published: (2020)

Simplification of two-dimensional gel patterns of HLA class II antigens.
by: Rust, N, et al.
Published: (1986)

HLA class I typing by PCR: HLA-B27 and an African B27 subtype.
by: Hill, A, et al.
Published: (1991)

HLA B27 can form heavy chain homodimers in vivo and in vivo, possible role of cys 67.
by: Bowness, P, et al.
Published: (1998)

Evidence of widespread binding of HLA class I molecules to peptides.
by: Frelinger, J, et al.
Published: (1990)

Anti-HLA-A2 antibody-enhancement of peptide association with HLA-A2 as detected by cytotoxic T lymphocytes.
by: Bodmer, H, et al.
Published: (1989)

T-cell immunotherapy of allergic disease: the role of CD8+ T cells.
by: Ogg, G
Published: (2003)

T-cell-targeted immunotherapy.
by: Feldmann, M, et al.
Published: (1992)

HLA class I and class II associations in dengue viral infections in a Sri Lankan population
by: Malavige, G, et al.
Published: (2011)

HLA class I and class II associations in dengue viral infections in a Sri Lankan population.
by: Malavige, G, et al.
Published: (2011)

The emerging role of exosome and microvesicle- (EMV-) based cancer therapeutics and immunotherapy
by: Moore, Colin, et al.
Published: (2017)

Drug-device development: cancer immunotherapy with therapeutic, ultrasound-mediated delivery
by: Katti, PS
Published: (2020)

HLA class II induction in human islet cells by interferon-gamma plus tumour necrosis factor or lymphotoxin.
by: Pujol-Borrell, R, et al.
Published: (1987)

InVivo Therapeutics® Corporation
by: Reynolds, Francis M., M.B.A. Massachusetts Institute of Technology
Published: (2007)

ELISPOT and functional T cell analyses using HLA mono-specific target cells.
by: Horlock, C, et al.
Published: (2009)

Interethnic genetic differentiation in Africa: HLA class I antigens in The Gambia.
by: Allsopp, C, et al.
Published: (1992)

Macrophage-tumour interactions: In vivo dynamics
by: Byrne, H, et al.
Published: (2004)

Structure and function of the human MHC class Ib molecules HLA-E, HLA-F and HLA-G.
by: O'Callaghan, C, et al.
Published: (1998)

Inefficient cytotoxic T lymphocyte-mediated killing of HIV-1-infected cells in vivo
by: Asquith, B, et al.
Published: (2006)

Biguanide-derived polymeric nanoparticles kill MRSA biofilm and suppress infection in vivo
by: Li, Jianghua, et al.
Published: (2020)

Inefficient cytotoxic T lymphocyte-mediated killing of HIV-1-infected cells in vivo.
by: Asquith, B, et al.
Published: (2006)

Inefficient cytotoxic T lymphocyte-mediated killing of HIV-1-infected cells in vivo
by: Asquith, B, et al.
Published: (2006)

Tetrameric complexes of HLA-E, HLA-F, and HLA-G.
by: Allan, D, et al.
Published: (2002)

How to kill stress before it kills you/
by: 455944 Culligan, Matthew J., et al.
Published: (1976)

In vivo generation of 'vaccination nodes' using injectable alginate hydrogels for cancer immunotherapy
by: Hori, Yuki
Published: (2010)

HIV and HLA class I: an evolving relationship.
by: Goulder, P, et al.
Published: (2012)